Examination with PET/ MRI for patients with laryngeal cancer.
Imaging with PET/MRI is useful for primary staging of laryngeal cancer, according to a study in the European Journal of Radiology.
Researchers from Italy sought to assess the clinical impact of PET/MRI examination on patients with histologically proven laryngeal cancer, and their staging and treatment planning.
Sixteen patients underwent whole body PET/CT followed by a dedicated head/neck PET/MRI. Two blinded groups evaluated the data: metabolic (SUV and MTV), diffusion (ADC) and perfusion (Ktrans, Ve, kep, and iAUC) maps were obtained by positioning regions of interest (ROIs). Tumoral local extension assessed on PET/MRI was compared to endoscopic findings.
The results showed a good interobserver agreement in anatomical location and local extension of PET/MRI lesions. “PET/CT SUV measures highly correlate with ones derived by PET/MRI (eg, pâ =â 0.96 for measures on VOI),” the authors wrote. “Significant correlations among metabolic, diffusion and perfusion parameters have been detected.” The researchers noted that PET/MRI had a relevant clinical impact, confirming endoscopic findings (six cases), helping treatment planning (nine cases), and modifying endoscopic primary staging (one case).
The researchers concluded that use of PET/MRI in primary staging of laryngeal cancer allowed simultaneous collection of metabolic and functional data and conditioning the therapeutic strategies.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.